Allogene Therapeutics officer proposes $48.7K share sale

A 100,000-share restricted stock unit award is listed as vesting on October 20, 2026.

Rhea-AI Filing Summary

Allogene Therapeutics, Inc. officer Geoffrey M. Parker reported a proposed sale of 36,342 common shares, with an approximate sale date of October 21, 2026, through Morgan Stanley Smith Barney LLC on Nasdaq. The notice lists an aggregate market value of $48,698.28. It also reports that 100,000 common shares were acquired on October 20, 2026, through vesting of a restricted stock unit award under the issuer’s equity compensation plan.

Key Figures

Proposed shares to be sold: 36,342 shares Aggregate market value: $48,698.28 Shares outstanding: 345,490,881 shares +1 more

4 metrics

Proposed shares to be sold 36,342 shares Common stock; approximate sale date October 21, 2026

Aggregate market value $48,698.28 Listed for the proposed sale

Shares outstanding 345,490,881 shares Issuer common stock

Shares acquired through RSU vesting 100,000 shares Vesting date October 20, 2026

Key Terms

restricted stock unit award, equity compensation plan, Rule 144

3 terms

restricted stock unit award financial

"Vesting of restricted stock unit award"

A restricted stock unit award is a promise by a company to give an employee a specified number of company shares at a future date if certain conditions are met, such as staying with the company or hitting performance goals. For investors, these awards matter because they can increase the total number of shares outstanding when converted, diluting existing holders, and they align employees’ incentives with shareholders’ interests much like giving a rising bonus that becomes real only after conditions are satisfied.

equity compensation plan financial

"Granted as part of issuer equity compensation plan"

A plan by which a company gives employees, directors or contractors ownership or the right to buy ownership in the company through stock, options or similar awards — think of promising slices of the company pie as part of someone's pay. It matters to investors because these awards can change the number of shares outstanding, affect reported profits and influence management’s decisions; large or generous plans can dilute existing holders and alter incentives over time.

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ALLO shares did Geoffrey M. Parker propose to sell?

Geoffrey M. Parker, identified as an officer, reported a proposed sale of 36,342 common shares, with an approximate sale date of October 21, 2026. The notice lists Morgan Stanley Smith Barney LLC and Nasdaq for the proposed transaction, and an aggregate market value of $48,698.28.

How many ALLO shares vested for Geoffrey M. Parker?

The notice reports that 100,000 common shares were acquired on October 20, 2026, through vesting of a restricted stock unit award granted as part of Allogene Therapeutics, Inc.’s equity compensation plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/21/2026 - 07:48 PM EDT Accepted by SEC EDGAR 10/21/2026 - 07:48 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001491874
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Allogene Therapeutics, Inc.
SEC File Number	001-38693
Address of Issuer	210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CALIFORNIA 94080
Phone	(650) 457-2700
Name of Person for Whose Account the Securities are To Be Sold	Parker Geoffrey M.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza New York NY 10004	36342	48698.28	345490881	10/21/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	10/20/2026	Vesting of restricted stock unit award	Allogene Therapeutics, Inc.			100000	10/20/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	10/21/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	GEOFFREY PARKER
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)